Abstract | OBJECTIVE: PATIENTS AND METHODS: RESULTS: The complete hematologic, cytogenetic, and molecular response rates were 50% (3/6), 71% (5/7), and 75% (9/12), respectively. Two cases of grade 2 cytokine release syndrome were observed, all of which resolved with steroids and tocilizumab. No cardiovascular adverse events were encountered. With a median follow-up of 8 months, the median survival was not reached; the 6-month and 1-year overall survival rates were 73%. CONCLUSIONS: The combination of blinatumomab with TKI is safe and effective in patients with relapsed/refractory Ph+ disease. Prospective studies are warranted.
|
Authors | Rita Assi, Hagop Kantarjian, Nicholas J Short, Naval Daver, Koichi Takahashi, Guillermo Garcia-Manero, Courtney DiNardo, Jan Burger, Jorge Cortes, Nitin Jain, William Wierda, Salim Chamoun, Marina Konopleva, Elias Jabbour |
Journal | Clinical lymphoma, myeloma & leukemia
(Clin Lymphoma Myeloma Leuk)
Vol. 17
Issue 12
Pg. 897-901
(Dec 2017)
ISSN: 2152-2669 [Electronic] United States |
PMID | 28927784
(Publication Type: Journal Article)
|
Copyright | Copyright © 2017 Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Bispecific
- Protein Kinase Inhibitors
- blinatumomab
- Fusion Proteins, bcr-abl
|
Topics |
- Adult
- Aged
- Antibodies, Bispecific
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Drug Resistance, Neoplasm
- Fusion Proteins, bcr-abl
(genetics)
- Humans
- Kaplan-Meier Estimate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy, genetics)
- Middle Aged
- Neoplasm Recurrence, Local
- Protein Kinase Inhibitors
(administration & dosage)
- Retrospective Studies
- Treatment Outcome
|